NO973402L - Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranaloger - Google Patents
Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranalogerInfo
- Publication number
- NO973402L NO973402L NO973402A NO973402A NO973402L NO 973402 L NO973402 L NO 973402L NO 973402 A NO973402 A NO 973402A NO 973402 A NO973402 A NO 973402A NO 973402 L NO973402 L NO 973402L
- Authority
- NO
- Norway
- Prior art keywords
- therapy
- analogs
- aza
- contraception
- well
- Prior art date
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title 2
- 239000004471 Glycine Substances 0.000 title 1
- 102000011714 Glycine Receptors Human genes 0.000 title 1
- 108010076533 Glycine Receptors Proteins 0.000 title 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 3
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 238000009232 chiropractic Methods 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37969995A | 1995-01-27 | 1995-01-27 | |
| US08/466,043 US5801183A (en) | 1995-01-27 | 1995-06-06 | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| PCT/US1995/016575 WO1996022990A2 (en) | 1995-01-27 | 1995-12-21 | Aza and aza (n-oxy) analogs of glycine/nmda receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO973402D0 NO973402D0 (no) | 1997-07-23 |
| NO973402L true NO973402L (no) | 1997-09-17 |
Family
ID=27008733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO973402A NO973402L (no) | 1995-01-27 | 1997-07-23 | Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranaloger |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5801183A (de) |
| EP (1) | EP0805809A2 (de) |
| JP (1) | JP2002515012A (de) |
| KR (1) | KR19980701668A (de) |
| AU (1) | AU718748B2 (de) |
| BR (1) | BR9510265A (de) |
| CA (1) | CA2211608A1 (de) |
| FI (1) | FI973047A7 (de) |
| NO (1) | NO973402L (de) |
| NZ (1) | NZ300778A (de) |
| WO (1) | WO1996022990A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1307451A2 (de) | 2000-08-04 | 2003-05-07 | Warner-Lambert Company Llc | Verfahren zur herstellung von 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrymidin-7-onen |
| US20020187295A1 (en) * | 2001-05-15 | 2002-12-12 | Fuji Photo Film Co., Ltd. | Magnetic transfer master medium |
| EP1467970B1 (de) * | 2002-01-17 | 2007-08-22 | Merck & Co., Inc. | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
| HUP0500200A2 (hu) * | 2002-01-17 | 2005-07-28 | Neurogen Corporation | Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények |
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| AU2003265740B8 (en) * | 2002-10-04 | 2010-06-03 | Prana Biotechnology Limited | Neurologically-active compounds |
| JP4690043B2 (ja) | 2002-10-04 | 2011-06-01 | プラナ バイオテクノロジー リミティッド | 神経に対し活性な化合物 |
| EP1648890A2 (de) * | 2003-07-18 | 2006-04-26 | Basf Aktiengesellschaft | Arylkondensierte 3-arylpyridinverbindungen und ihre verwendung zur bekämpfung von schadpilzen |
| US7625949B2 (en) | 2004-04-23 | 2009-12-01 | Roche Palo Alto Llc | Methods for treating retroviral infections |
| US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
| CN101291905A (zh) | 2005-10-19 | 2008-10-22 | 弗·哈夫曼-拉罗切有限公司 | 苯乙酰胺nnrt抑制剂 |
| CN101534826A (zh) | 2006-04-14 | 2009-09-16 | 普拉纳生物技术有限公司 | 治疗与年龄相关的黄斑变性（amd）的方法 |
| AU2007268749B2 (en) * | 2006-05-26 | 2012-07-26 | Taisho Pharmaceutical Co., Ltd. | Novel heterocyclic compound or salt thereof and intermediate thereof |
| GB0614471D0 (en) | 2006-07-20 | 2006-08-30 | Syngenta Ltd | Herbicidal Compounds |
| GB0800855D0 (en) * | 2008-01-17 | 2008-02-27 | Syngenta Ltd | Herbicidal compounds |
| US8338337B2 (en) * | 2008-10-29 | 2012-12-25 | Basf Se | Substituted pyridines having a herbicidal effect |
| BRPI1008214A2 (pt) | 2009-06-05 | 2015-08-25 | Basf Se | "composto de pirazina da fórmula i, composto da fórmula i, processo para preparar o composto da fórmula i, composição e método para controlar uma vegetação indesejável" |
| BRPI1011784A2 (pt) * | 2009-06-18 | 2016-03-22 | Pfizer | compostos bicíclicos e tricíclicos como inibidores de kat ii |
| WO2011117195A1 (en) * | 2010-03-23 | 2011-09-29 | Basf Se | Substituted pyridines having herbicidal action |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| MX393950B (es) | 2017-06-12 | 2025-03-24 | Glytech Llc | Composicion y metodo para el tratamiento de la depresion y psicosis en humanos |
| CN114369069B (zh) * | 2022-01-21 | 2024-03-15 | 江苏丰山生化科技有限公司 | 一种精喹禾灵环合物中间体的制备方法 |
| CN114957222B (zh) * | 2022-05-31 | 2023-08-15 | 内蒙古民族大学 | 化合物及其制备方法和用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1490998A (en) * | 1975-09-23 | 1977-11-09 | Beecham Group Ltd | Nitronaphthylridine derivatives and pharmaceutical compositions comprising them |
| US4103257A (en) * | 1976-05-25 | 1978-07-25 | The United States Of America As Represented By The United States Department Of Energy | Azaquinolone dye lasers |
| US4128649A (en) * | 1977-06-29 | 1978-12-05 | Sandoz, Inc. | 4-Hydroxy-pyrido[2,3-b]pyridine-2(1H)-one-3-carboxylic acids and esters |
| US4215123A (en) * | 1979-05-07 | 1980-07-29 | American Home Products Corporation | Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| US5268378A (en) * | 1990-05-31 | 1993-12-07 | Merck Sharp & Dohme, Limited | Dioxo-tetrahydroquinoline derivatives |
| DE69113115T2 (de) * | 1990-05-31 | 1996-06-13 | Merck Sharp & Dohme | Dioxo-tetrahydrochinolinderivate. |
| HU221425B (en) * | 1990-11-06 | 2002-10-28 | Yamanouchi Pharma Co Ltd | Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds |
| JPH04178385A (ja) * | 1990-11-09 | 1992-06-25 | Yamanouchi Pharmaceut Co Ltd | ジケトピリドピラジン誘導体 |
| GB9026389D0 (en) * | 1990-12-05 | 1991-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| AU9049391A (en) * | 1990-12-20 | 1992-07-22 | Warner-Lambert Company | 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity |
| IL101860A0 (en) * | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| US5196421A (en) * | 1991-06-05 | 1993-03-23 | Eli Lilly And Company | Excitatory amino acid receptor antagonists in methods for the use thereof |
| EP0647137B1 (de) * | 1992-06-22 | 2008-08-13 | The Regents Of The University Of California | Glycinrezeptorantagonisten und ihre verwendung |
| TW274550B (de) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| US5622965A (en) * | 1993-03-12 | 1997-04-22 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists |
| US5475007A (en) * | 1993-05-28 | 1995-12-12 | The Regents Of The University Of California | 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof |
-
1995
- 1995-06-06 US US08/466,043 patent/US5801183A/en not_active Expired - Lifetime
- 1995-12-21 WO PCT/US1995/016575 patent/WO1996022990A2/en not_active Ceased
- 1995-12-21 AU AU46024/96A patent/AU718748B2/en not_active Ceased
- 1995-12-21 JP JP52285296A patent/JP2002515012A/ja not_active Ceased
- 1995-12-21 NZ NZ300778A patent/NZ300778A/xx not_active IP Right Cessation
- 1995-12-21 EP EP95944152A patent/EP0805809A2/de not_active Withdrawn
- 1995-12-21 KR KR1019970705064A patent/KR19980701668A/ko not_active Withdrawn
- 1995-12-21 CA CA002211608A patent/CA2211608A1/en not_active Abandoned
- 1995-12-21 BR BR9510265A patent/BR9510265A/pt not_active Application Discontinuation
-
1997
- 1997-07-18 FI FI973047A patent/FI973047A7/fi not_active Application Discontinuation
- 1997-07-23 NO NO973402A patent/NO973402L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU4602496A (en) | 1996-08-14 |
| BR9510265A (pt) | 1997-11-04 |
| FI973047A7 (fi) | 1997-08-28 |
| WO1996022990A3 (en) | 1996-10-10 |
| FI973047A0 (fi) | 1997-07-18 |
| KR19980701668A (ko) | 1998-06-25 |
| JP2002515012A (ja) | 2002-05-21 |
| NZ300778A (en) | 1999-01-28 |
| EP0805809A2 (de) | 1997-11-12 |
| AU718748B2 (en) | 2000-04-20 |
| NO973402D0 (no) | 1997-07-23 |
| US5801183A (en) | 1998-09-01 |
| CA2211608A1 (en) | 1996-08-01 |
| WO1996022990A2 (en) | 1996-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO973402L (no) | Aza- og aza(N-oxy)analoger av glycin/NMDA-reseptoranaloger | |
| AU2015237245B2 (en) | Potent soluble epoxide hydrolase inhibitors | |
| DE69334237D1 (de) | Glycinrezeptorantagonisten und ihre verwendung | |
| YU57599A (sh) | Primena derivata fumarne kiseline | |
| US6380220B1 (en) | Derivatives from piperidine-keto acid, their preparation and use | |
| TW201416340A (zh) | Ａｔｘ調節劑 | |
| WO1995018616A3 (en) | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor | |
| TW201402537A (zh) | 犬尿胺酸－３－單氧化酶抑制劑，其醫藥組成物及使用方法 | |
| DK0495982T3 (da) | Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel | |
| KR20180100453A (ko) | 오피오이드 수용체 리간드와 그 용도 및 제조방법 | |
| NO934501L (no) | Karboksylsyrederivater, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling | |
| MXPA05009524A (es) | Derivados de imidazol-4-il-etinil-piridina. | |
| HRP20000776A2 (en) | New substituted amides, their production and their use | |
| EP0664289A3 (de) | Isochinoline | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| CA2793138C (en) | Hydroxybenzoate salts of metanicotine compounds | |
| IE902849A1 (en) | Novel compounds | |
| GR3031901T3 (en) | Substituted pyrroles. | |
| CN109983012A (zh) | 赖氨酸牙龈蛋白酶的酮抑制剂 | |
| JO2260B1 (en) | Piperidine ethanesulfonyl derivatives | |
| TW201418198A (zh) | 轉麩醯胺酸酶ｔｇ２抑制劑，醫藥組成物及其使用方法 | |
| El Oualid et al. | Design, Synthesis, and Evaluation of Su-gar Amino Acid Based Inhibitors of Pro-tein Prenyl Transferases PFT and PGGT-1 | |
| CA2360326A1 (en) | Use of 4-amino pyridine for treatment of peripheral neuropathies | |
| EP1270007A3 (de) | Mikroemulsionen zur transdermalen Verabreichung von Apomorphin für die Behandlung von der parkinsonschen Krankheit | |
| US6787564B2 (en) | Optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |